Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Non-Current Deffered Revenue (2022 - 2023)

TriSalus Life Sciences' Non-Current Deffered Revenue history spans 2 years, with the latest figure at $8.8 million for Q2 2023.

  • For Q2 2023, Non-Current Deffered Revenue changed 0.0% year-over-year to $8.8 million; the TTM value through Jun 2023 reached $8.8 million, changed 0.0%, while the annual FY2022 figure was $8.8 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $8.8 million in Q2 2023 per TLSIW's latest filing, roughly flat from $8.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $8.8 million in Q1 2022 to a low of $8.8 million in Q1 2022.